275 related articles for article (PubMed ID: 28905271)
1. Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D
Pandey R; Zella JB; Zhu JG; Plum LA; Clagett-Dame M; Blaser WJ; Bedale W; DeLuca HF; Coyne DW
Drugs R D; 2017 Dec; 17(4):597-605. PubMed ID: 28905271
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. 2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial.
Thadhani R; Zella JB; Knutson DC; Blaser WJ; Plum LA; Clagett-Dame M; Buck RD; DeLuca HF
Am J Nephrol; 2017; 45(1):40-48. PubMed ID: 27880946
[TBL] [Abstract][Full Text] [Related]
4. Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism.
Pandey R; Zella J; Clagett-Dame M; Plum LA; DeLuca HF; Coyne DW
Am J Nephrol; 2016; 43(3):213-20. PubMed ID: 27096733
[TBL] [Abstract][Full Text] [Related]
5. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
Zella JB; Plum LA; Plowchalk DR; Potochoiba M; Clagett-Dame M; DeLuca HF
Am J Nephrol; 2014; 39(6):476-83. PubMed ID: 24854296
[TBL] [Abstract][Full Text] [Related]
6. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
7. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
8. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
[TBL] [Abstract][Full Text] [Related]
9. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
[TBL] [Abstract][Full Text] [Related]
10. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
[TBL] [Abstract][Full Text] [Related]
12. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
13. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
14. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients.
Levine BS; Song M
J Am Soc Nephrol; 1996 Mar; 7(3):488-96. PubMed ID: 8704116
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
[TBL] [Abstract][Full Text] [Related]
17. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
Kasai K; Abe R; Wakabayashi M; Nakamura K; Sawatani S; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2002; 44(5):464-70. PubMed ID: 12216479
[TBL] [Abstract][Full Text] [Related]
18. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
